Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 The cumulative incidence rate of adverse events associated with pentavalent vaccination in male and female children and related risk ratios

From: Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran

Adverse events Incidence (per 100 children) P-value Risk ratio (95% CI)a
Sex
Male Female
Swelling Yes 103(16.9) 74(14.5) 0.149 1.16 (0.88–1.50)
No 505(83.1) 437(85.5)
Redness Yes 64(10.5) 59(11.5) 0.327 0.91 (0.65–1.27)
No 544(89.5) 452(88.5)
Pain Yes 282(53.6) 213(41.7) 0.065 1.11 (0.97–1.27)
No 326(53.6) 298(58.3)
Mild fever Yes 75(12.3) 66(12.9) 0.420 0.95 (0.70–1.30)
No 533(87.7) 445(87.1)
High fever Yes 0 1(0.2) 0.457 NA
No 608(100) 510(99.8)
Drowsiness Yes 123(20.2) 102(20) 0.486 1.01 (0.80–1.28)
No 485(79.8) 409(80)
Anorexia Yes 91(15) 77(15.1) 0.514 0.99 (0.75–1.31)
No 517(85) 434(84.9)
Restlessness Yes 204(33.6) 165(32.3) 0.351 1.03 (0.87–1.22)
No 404(66.4) 346(67.7)
Vomiting Yes 29(4.8) 23(4.5) 0.474 1.05 (0.62–1.80)
No 579(95.2) 488(95.5)
Long-term crying Yes 43(7.1) 19(3.7) 0.010 1.90 (1.13–3.22)
No 565(92.9) 492(96.3)
Encephalopathy Yes 0 0 1 NA
No 608(100) 511(100)
Convulsion Yes 0 0 1 NA
No 608(100) 511(100)
History of convulsion Yes 3(0.49) 0 0.43 NA
No 605(99.5) 511(100)
Family history of convulsion Yes 10(1.64) 10(1.9) 0.16 0.84 (0.35–2)
No 598(98.3) 501(98.0)
  1. NA not applicable
  2. aFemale gender was considered as reference for RR calculation